Xenon (XENE) AI Stock Analysis

• Market Cap: $4.55B
• Dividend Yield: N/A
• Average Volume (3M): 1.63M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: N/A
• EPS Growth: -38.30%
• Country: US
• Employees: 316
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.31
• Shares Outstanding: 83,190,315
• 10 Day Avg. Volume: 3,349,302
• 30 Day Avg. Volume: 1,631,112
• PEG Ratio: -0.23
• Price to Book (P/B): 6.11
• Price to Sales (P/S): 473.62
• P/FCF Ratio: -12.69
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 580.80
• Enterprise Value/Gross Profit: -61.53
• Enterprise Value/Ebitda: -12.12
• 1Y Price Target: $75.82
• Price Target Upside: 38.71% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19
• EPS Forecast (FY): -4.83
• Revenue Forecast (FY): $5.45M

• Rating: 62 Neutral
• Price Target: $61.00 ▲(11.60% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is primarily constrained by weak financial performance (large losses and heavy cash burn), but supported by a strong balance sheet and extended cash runway reinforced by recent financing. Technicals are favorable with a strong uptrend, though overbought signals temper the near-term setup. Earnings call commentary and milestones provide a constructive outlook, while valuation remains challenged due to ongoing unprofitability and no dividend support.

Positive Factors

Strong balance sheet and liquidity

The sizable recent equity raise and existing cash position create a multi-year funding runway that materially reduces near-term financing risk. This durable liquidity allows Xenon to complete late‑stage programs, invest in commercialization planning, and pursue early-stage assets without immediate revenue dependency.

Strong Phase III execution and trial power

Exceeding enrollment targets reflects operational execution and patient recruitment capability, increasing the likelihood the study will yield definitive results. Reliable trial conduct is a durable competitive capability that de-risks regulatory timelines and supports future commercial planning if efficacy is confirmed.

Pipeline diversification across indications and stages

A multi-indication late‑stage program plus early-stage ion channel candidates provides multiple value pathways and spreads binary trial risk. Platform expertise in ion channels supports sustained discovery and repositioning opportunities, improving long-term odds of commercial success across neurology and neuropsychiatry markets.

Negative Factors

High operating cash burn

Persistent, large negative operating and free cash flows mean Xenon consumes material capital to fund development. Even with current liquidity, sustained burn forces recurring financing or steep operational tradeoffs absent near-term commercialization, making long‑term funding strategy a critical structural risk factor.

Minimal revenue and widening net losses

Very low and inconsistent commercial revenue alongside large, widening losses indicate the company remains far from self-sustaining cash generation. This structural unprofitability increases dependence on capital markets and heightens execution risk for converting trials into profitable products over the medium term.

Ongoing reliance on equity financing (dilution risk)

Repeated and sizable equity raises and an active ATM program signal structural reliance on external capital to fund operations. While they extend runway, continued issuance dilutes existing shareholders and may compress long‑term returns if the company cannot transition to internally generated cash flows after product commercialization.

Xenon Business Overview & Revenue Model

Company Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Financial Statement Overview

Summary

Balance sheet strength (very low debt and substantial liquidity runway) is partially offset by very weak operating fundamentals: minimal revenue, large and widening net losses, and heavy ongoing cash burn with negative free cash flow.

Income Statement

The income statement remains weak, with recurring large net losses and deeply negative profitability. Revenue is inconsistent (including multiple years with zero revenue) and TTM (Trailing-Twelve-Months) shows only $7.5M of revenue against a net loss of ~$346M, reflecting a cost structure that is far ahead of commercial scale. While this is not unusual for a clinical-stage biotech, the trend is unfavorable with losses widening meaningfully from 2024 to TTM.

Balance Sheet

The balance sheet is a clear strength: leverage is very low (TTM total debt ~$7.9M vs. equity ~$633M, debt-to-equity ~0.01). However, equity has declined materially from 2023 to TTM, consistent with ongoing losses and cash burn, and returns on equity are sharply negative. Overall, the company appears well-capitalized with minimal debt risk, but the equity base is being pressured by continued operating deficits.

Cash Flow

Cash flow quality is pressured by persistent operating cash burn and negative free cash flow. TTM operating cash flow is about -$279M and free cash flow about -$280M, worsening versus 2024, indicating an accelerating spend profile. A positive note is that cash burn broadly tracks reported losses (free cash flow is roughly in line with net income), suggesting losses are not being masked by working-capital timing; however, the magnitude of burn remains a key risk without a step-change in revenue or funding.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.50M	0.00	0.00	9.43M	18.44M
Gross Profit	4.96M	-2.56M	-167.51M	9.43M	18.44M
EBITDA	-342.35M	-235.86M	-210.51M	-127.74M	-78.09M
Net Income	-345.91M	-234.33M	-182.39M	-125.37M	-78.88M
Balance Sheet
Total Assets	981.67M	798.14M	964.80M	754.15M	572.01M
Cash, Cash Equivalents and Short-Term Investments	548.89M	626.90M	638.08M	592.09M	551.77M
Total Debt	7.94M	9.02M	10.90M	10.44M	8.26M
Total Liabilities	399.91M	43.24M	36.88M	32.65M	21.97M
Stockholders Equity	581.76M	754.90M	927.92M	721.50M	550.03M
Cash Flow
Free Cash Flow	-279.92M	-184.46M	-150.94M	-101.32M	-71.55M
Operating Cash Flow	-279.12M	-181.39M	-145.33M	-98.43M	-69.50M
Investing Cash Flow	218.00M	165.00M	-117.17M	-296.00M	-246.77M
Financing Cash Flow	117.11M	12.13M	353.52M	278.47M	447.54M

Xenon Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 54.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XENE, the sentiment is Positive. The current price of 54.66 is above the 20-day moving average (MA) of 47.66, above the 50-day MA of 44.06, and above the 200-day MA of 39.19, indicating a bullish trend. The MACD of 3.84 indicates Negative momentum. The RSI at 62.50 is Neutral, neither overbought nor oversold. The STOCH value of 64.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XENE.

Xenon Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XENE	62 Neutral	$4.55B	-10.27	-55.81%	―	―	-38.30%
IMVT	62 Neutral	$5.09B	-10.43	-65.80%	―	―	-27.70%
MLYS	56 Neutral	$2.12B	-15.88	-32.94%	―	―	9.60%
SRRK	54 Neutral	$4.63B	-13.37	-145.91%	―	―	-31.71%
VKTX	52 Neutral	$4.16B	-6.36	-48.04%	―	―	-126.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RARE	49 Neutral	$2.11B	-3.94	-1024.42%	―	20.63%	8.09%

Xenon Corporate Events

Xenon Strengthens Balance Sheet With Major Equity Offering

On March 10, 2026, Xenon Pharmaceuticals Inc. entered into an underwriting agreement for an underwritten public offering of 12,236,843 common shares and pre-funded warrants to purchase 877,194 common shares, priced to the public at $57.00 per share and $56.9999 per warrant. The underwriters, led by J.P. Morgan, Jefferies, TD Securities, Stifel, RBC Capital Markets and William Blair, agreed to purchase the securities at a discount to the public price.

The banks exercised in full a 30-day option on March 11, 2026 to buy an additional 1,710,526 common shares, bringing total net proceeds for Xenon to approximately $707.7 million after fees and expenses, with the offering closing on March 12, 2026. The deal, issued off an automatic shelf registration, significantly strengthens Xenon’s balance sheet and provides expanded financial flexibility, while the detailed pre-funded warrant terms are structured to manage beneficial ownership limits and protect holders in the event of major corporate transactions.

The most recent analyst rating on (XENE) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.

Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program

On February 27, 2026, Xenon Pharmaceuticals Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to register $400 million of common shares under its existing at-the-market equity offering sales agreement with Jefferies LLC and Stifel, Nicolaus & Company, Incorporated. The new prospectus supplement replaces and supersedes a prior prospectus, under which Xenon had already sold about $291.1 million in shares, signaling a refreshed ATM capacity that may support the company’s ongoing financing needs and capital markets strategy.

The company’s issuance and sale of shares under the sales agreement will be conducted pursuant to an automatically effective shelf registration statement on Form S-3 filed on August 9, 2024, together with a base prospectus dated the same day. An associated legal opinion on the validity of the shares has been filed, reinforcing the formal completion of regulatory steps required for Xenon to continue raising equity capital through the ATM program.

The most recent analyst rating on (XENE) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.

Xenon Highlights 2025 Results and Expands Late-Stage Pipeline

On Feb. 26, 2026, Xenon Pharmaceuticals reported its fourth-quarter and full-year 2025 results, highlighting heavy investment in late-stage development of azetukalner across epilepsy and neuropsychiatric indications. The company is advancing multiple Phase 3 programs, including X-TOLE2 and X-TOLE3 in focal onset seizures, X-ACKT in primary generalized tonic-clonic seizures, and X-NOVA and X-CEED in depression and bipolar disorder, supported by 48‑month open-label data showing sustained seizure reduction and long-term safety.

Xenon is also progressing early-stage NaV1.7 and KV7 candidates XEN1701 and XEN1120 in Phase 1 pain studies and continuing IND-enabling work on a NaV1.1 program for Dravet syndrome, while its partnered NaV1.2/NaV1.6 inhibitor with Neurocrine remains in Phase 1. To fund this pipeline, the company raised $242.2 million via at-the-market equity sales, ending 2025 with $586 million in cash and pro forma liquidity of $716 million, which it expects will support operations into the second half of 2027 despite a 2025 net loss of $345.9 million driven by expanded R&D and higher operating costs.

The most recent analyst rating on (XENE) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.